Physician profile
David Bender
NPI 1891892626
$1,176.20
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $83.46 · 2022: $463 · 2023: $220 · 2024: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $263.94 | 2019-2023 | |
| Abbvie INC. | $159.08 | 2022-2023 | Dalvance |
| Novo Nordisk INC | $127.58 | 2019-2024 | Rybelsus, Ozempic |
| Eisai INC. | $100.46 | 2024 | |
| Novartis Pharmaceuticals Corporation | $72.85 | 2022-2023 | |
| Averitas Pharma INC. | $60.25 | 2023 | Qutenza |
| Ethicon US, LLC | $53.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.12 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $47.48 | 2024 | Keveyis |
| Astrazeneca Pharmaceuticals Lp | $45.10 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $44.33 | 2019-2020 | |
| Lilly USA, LLC | $37.83 | 2022-2023 | Mounjaro, Trulicity |
| Allergan, INC. | $26.78 | 2020 | |
| Insulet Corporation | $24.13 | 2023 | Omnipod |
| Genentech USA, INC. | $22.38 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strongbridge US INC. | $15.99 | 2020 | |
| Dexcom, INC. | $12.89 | 2022 | |
| Glaxosmithkline, LLC. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.